Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Darotropium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 20/20 | 1.00 |
| ▸ | CHRM2 known ✓ | P08172 | 4/20 | 1.00 |
| ▸ | CHRM1 known ✓ | P11229 | 4/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Darotropium SCHEMBL524037 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1 | |
| Darotropium SCHEMBL140648 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1 | |
| Darotropium SCHEMBL140647 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1 | |
| Darotropium SCHEMBL29504618 | 0.99 | CHRM3 (0.97) | CHRM3CHRM2CHRM1 | |
| Darotropium SCHEMBL3682091 | 0.99 | CHRM3 (0.97) | CHRM3CHRM2CHRM1 | |
| Darotropium SCHEMBL16781068 | 0.99 | CHRM3 (0.97) | CHRM3CHRM2CHRM1 | |
| Darotropium SCHEMBL3682092 | 0.99 | CHRM3 (0.97) | CHRM3CHRM2CHRM1 | |
| Darotropium SCHEMBL146665 | 0.97 | CHRM3 (0.94) | CHRM3CHRM2CHRM1 | |
| Darotropium SCHEMBL146666 | 0.97 | CHRM3 (0.94) | CHRM3CHRM2CHRM1 | |
| Bromide SCHEMBL4631510 | 0.94 | CHRM3 (0.90) | CHRM3CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12636447-B2 | Dry powder inhaler with an adherence/compliance monitor | VECTURA DELIVERY DEVICES LIMITED (GB) | 2026-05-26 | — | — | US | disclosed |
| EP-3646870-B1 | COMPOSITIONS FOR TREATMENT OF DISORDERS AMELIORATED BY MUSCARINIC RECEPTOR ACTIVATION | PureTech Health LLC (US) | 2026-05-20 | — | — | EP | disclosed |
| US-20260124147-A1 | THERAPEUTIC METHODS AND COMPOSITIONS FOR TREATING MOVEMENT DISORDERS | Vima Therapeutics, Inc. (US) | 2026-05-07 | — | — | US | disclosed |
| US-20250339418-A1 | THERAPEUTIC METHODS AND COMPOSITIONS FOR TREATING MOVEMENT DISORDERS | Vima Therapeutics, Inc. (US) | 2025-11-06 | — | — | US | disclosed |
| US-12427270-B2 | Inhaler for use with a compliance monitor | VECTURA DELIVERY DEVICES LIMITED (GB) | 2025-09-30 | — | — | US | disclosed |
| US-20250268883-A1 | THERAPEUTIC METHODS AND COMPOSITIONS FOR TREATING MOVEMENT DISORDERS | Vima Therapeutics, Inc. (US) | 2025-08-28 | — | — | US | disclosed |
| US-12290513-B2 | Therapeutic methods and compositions for treating movement disorders | Vima Therapeutics, Inc. (US) | 2025-05-06 | — | — | US | disclosed |
| EP-4340915-B1 | ADHERENCE MONITOR FOR A DRY POWDER INHALER | VECTURA DELIVERY DEVICES LTD (GB) | 2025-03-05 | — | — | EP | disclosed |
| EP-4333951-B1 | UNIT DOSE DRY POWDER INHALER | VECTURA DELIVERY DEVICES LTD (GB) | 2024-12-11 | — | — | EP | disclosed |
| EP-4114743-B1 | PROCESS FOR MANUFACTURING A BLISTER STRIP FOR A DRY POWDER INHALER | VECTURA DELIVERY DEVICES LTD (GB) | 2024-11-13 | — | — | EP | disclosed |
| US-20220251165-A1 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 LTD. (GB) | 2022-08-11 | — | — | US | disclosed |
| EP-4026898-A1 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 Ltd (GB) | 2022-07-13 | — | — | EP | disclosed |
| US-20220105519-A1 | JET MILLING METHOD | VECTURA LIMITED (GB) | 2022-04-07 | — | — | US | disclosed |
| CN-108135851-B | Jet milling method | 维克多瑞有限公司 | 2022-03-15 | — | — | CN | disclosed |
| WO-2022043336-A1 | UNIT DOSE DRY POWDER INHALER | VECTURA DELIVERY DEVICES LIMITED (GB) | 2022-03-03 | — | — | WO | disclosed |
| US-20220041684-A1 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 LTD. (GB) | 2022-02-10 | — | — | US | disclosed |
| EP-3947434-A2 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 Ltd (GB) | 2022-02-09 | — | — | EP | disclosed |
| US-11235112-B2 | Inhalable dry powders | PULMATRIX OPERATING COMPANY, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| EP-3689339-B1 | JET MILLING METHOD | VECTURA LTD (GB) | 2022-01-26 | — | — | EP | disclosed |
| US-11229915-B2 | Jet milling method | VECTURA LIMITED (GB) | 2022-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250268883-A1 | THERAPEUTIC METHODS AND COMPOSITIONS FOR TREATING MOVEMENT DISORDERS | CHRM3, CHRM5, CHRM2 | CHRM3 1/4885CHRM2 3/4885CHRM1 8/4885 |
| US-12290513-B2 | Therapeutic methods and compositions for treating movement disorders | CHRM3, CHRM5, CHRM2 | CHRM3 1/4885CHRM2 3/4885CHRM1 8/4885 |
| US-20250339418-A1 | THERAPEUTIC METHODS AND COMPOSITIONS FOR TREATING MOVEMENT DISORDERS | CHRM3, CHRM5, CHRM2 | CHRM3 1/4885CHRM2 3/4885CHRM1 8/4885 |
| US-20260124147-A1 | THERAPEUTIC METHODS AND COMPOSITIONS FOR TREATING MOVEMENT DISORDERS | CHRM5, CHRM4, CHRM2 | CHRM3 4/4885CHRM2 3/4885CHRM1 11/4885 |
| US-12636447-B2 | Dry powder inhaler with an adherence/compliance monitor | CHRM2, CHRM1, CHRM4 | CHRM3 5/4885CHRM2 1/4885CHRM1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.